As the world races to find a vaccine for COVID-19, our colleague Dr Cem Gun, an Emergency Medicine Physician at Acıbadem University Atakent Hospital, has bravely volunteered for the country’s first clinical trial. On 9 October, he was administered the first dose of a COVID-19 vaccine developed in China and approved for trial by the Health Institutes of Turkey, at a high-key milestone event.
On why he volunteered for this trial, Dr Cem Gun said, “As a healthcare worker, I fall into the high-risk group for COVID-19 infection. I decided to be vaccinated not only to protect myself but also my patients and loved ones. I made this decision with peace of mind as it is a controlled trial; it is currently in Phase 3, making it a tested and safe vaccine.”
The vaccine will be administered in two doses, and volunteers will be monitored on its effectiveness over a year.
The World Bank has approved US$12 billion in financing to help developing countries buy and distribute COVID-19 vaccines, tests and treatments, aiming to support the vaccination of up to 1 billion people.
Related Stories
.jpg?sfvrsn=21d67f46_1)
IHH Singapore Collaborates with Insurers to Improve Affordability of Private Hospital Care
Taking Preventive Health to New Heights at The IHH Sky Race | Merdeka 118
IHH Healthcare Malaysia highlights Care. For Good. through its role as title partner and official medical provider of The IHH Sky Race | Merdeka
Gleneagles Hospital Hong Kong Highlights Healthcare at ITB China 2026
Travel today is no longer defined by destinations alone — it is shaped by the confidence and assurance travellers carry with them.
IHH Malaysia Strengthens Care Integration Through GP-Specialist Collaboration
A referral is more than an appointment with another doctor, it is an act of trust.
Parkway MediCentre Xintiandi Launches Integrated Chinese and Western Medicine Health Management Services
Themed "Echoes of the World, Pulse of China", Parkway MediCentre Xintiandi showcased the role of Traditional Chinese Medicine (TCM) through an integrated healthcare approach.
Fortis Memorial Research Institute (FMRI) Launches India's First Centre of Excellence for Myeloma and Lymphoma
Officiated on 11 June, the FMRI Centre of Excellence, brings a highly specialised, patient‑centred and research‑driven approach to managing blood cancers.
